Gabapentin Capsule
Product Images NDC 69434-044

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69434-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zhejiang Yongtai Pharmaceutical Co., Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Gabapentincapsules 01)

An equation formula panel showing the calculation of creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients. The formula is presented as a mathematical expression combining these variables.*

FDA Label Image

Chemical Structure (Gabapentincapsules 02)

Chemical structure diagram of gabapentin, showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H). This structure represents the active ingredient gabapentin.*

FDA Label Image

Figure 1 (Gabapentincapsules 03)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score values from 0 to 10. Gabapentin scores decrease over time, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Gabapentincapsules 04)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain score values from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentincapsules 05)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. The chart compares response rates for placebo (PBO) and Gabapentin (GBP) at different dosages, highlighting a higher proportion of responders in Gabapentin groups compared to placebo, with statistical significance indicated by p-values.*

FDA Label Image

Figure 4 (Gabapentincapsules 06)

A scatter plot showing the percentage difference versus daily dose in mg for Gabapentin oral capsules. Three studies are represented with distinct markers: Study a (black squares), Study b (gray squares), and Study c (white squares). The daily doses range from 600 mg to 1800 mg, with differences between approximately 7% to 18%.*

FDA Label Image

100 mg (Gabapentincapsules 100mg 100s 07)

Gabapentin Capsules, USP 100 mg label for oral use, manufactured by Zhejiang Yongtai Pharmaceutical Co., Ltd. The label indicates a package of 100 capsules, highlights storage instructions at 20°C to 25°C with permitted excursions, includes an NDC 69434-042-04, and features a barcode and QR code for medication guide access.*

FDA Label Image

300 mg (Gabapentincapsules 300mg 100s 08)

Label for Gabapentin Capsules, USP 300 mg by Zhejiang Yongtai Pharmaceutical Co., Ltd. The label indicates each capsule contains 300 mg of gabapentin. The package size is 100 capsules. It includes storage instructions, dosage and use notes, a barcode, and a QR code for accessing the medication guide online.*

FDA Label Image

400 mg (Gabapentincapsules 400mg 100s 09)

This is a text panel for Gabapentin Capsules, USP, 400 mg strength. It includes storage instructions, manufacturer information (Zhejiang Yongtai Pharmaceutical Co., Ltd), dispensing guidelines, and a QR code linking to a medication guide. The panel also displays the NDC number 69434-044-04, package size of 100 capsules, and a barcode with serialization details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.